The Canadian Pulmonary Hypertension (PHA Canada)’s campaign for November, Pulmonary Hypertension Awareness Month, is called “Make the connection”
“Make the Connection”, is the theme of the Canadian Pulmonary Hypertension (PHA Canada)’s campaign for November awareness month. Ths campaign is about helping more healthcare professionals recognize pulmonary hypertension (PH) and connect patients and caregivers with information, resources, and support. Read more about how to join the campaign at this…
Read More
The US Pulmonary Hypertension Association (PHA) launches its “Living under pressure” campaign for November, Pulmonary Hypertension Awareness month
During Pulmonary Hypertension Awareness Month, the ‘Living Under Pressure’ campaign raises awareness of the medical realities of pulmonary hypertension and the everyday pressures that accompany living with a serious condition. Read more about how to contribute at this link on the Pulmonary Hypertension Association’s website
Read More
What’s new on the Pulmonary Hypertension Knowledge Sharing Platform – October 2026
October was a busy month for the pulmonary hypertension community. The Alliance for Pulmonary Hypertension added five new PEP Talks and, together with the European Pulmonary Fibrosis Federation (EU-PFF), held a webinar on pulmonary hypertension associated with interstitial lung disease. On the treatment front Gossamer Bio has submitted a New…
Read More
Extension Studies in Treprostinil Palmitil Inhalation Powder (TPIP) Show Promise in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), American Journal of Managed Care, October 20, 2026
At the annual meeting of the American College of Chest Physicians, October 18-21. 2026, Insmed presented new data on treprostinil palmitil inhalation powder. This is an investigational inhaled prostacyclin-pathway drug that is released slowly in the lungs, so a single daily dose works for 24 hours. Current inhaled treprostinil needs…
Read More
Five new PEP Talks now online in the dedicated section of this website
Have you watched our latest PEP Talks? In the five most recent videos: 🔹 Aygün Mengelli Tomur (Turkey) reflects on life after lung transplantation, gratitude to her donor, and the importance of organ donation. 🔹 Jolie Lizana (USA) draws on her experience as a person living with pulmonary arterial hypertension,…
Read More
Update on investigational formulation of inhaled rapamycin (mTOR inhibitor) for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome after lung transplant, October 9, 2026
Quince Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, has announced that it has changed its name to IRulya Therapeutics Inc. IRulya will be focused on advancing LAM-001, an investigational formulation of inhaled rapamycin (mTOR inhibitor) for multiple…
Read More
Pulmonary arterial hypertension (PAH) in the era of obesity: navigating phenotypes of pulmonary hypertension, Expert Review of Respiratory Medicine, October 22, 2026
An article published recently on the Expert Review of Medicine reviews the epidemiology of obesity and its impact on pulmonary arterial hypertension. The typical patient has changed over the years from a young, lean, woman to an older person with other conditions such as obesity, diabetes or heart disease. Obesity…
Read MoreFirst Report of Real World Utilization of an Activin Signaling Inhibitor in Patients With Severe Pulmonary Arterial Hypertension in the Middle East, Pulmonary Circulation, October 22, 2026
Researchers from a tertiary pulmonary hypertension expert center in Abu Dhabi, United Arab Emirates, conducted a retrospective single-center cohort study (PH RISE-ME) evaluating the real-world effectiveness and safety of sotatercept in adults with pulmonary arterial hypertension already on optimised background therapy. The findings reveal that adding sotatercept In this cohort…
Read More
Platelet–Albumin–Bilirubin Index (PALBI) for Predicting Hospitalization and Mortality in Pulmonary Hypertension, Circulation Journal, October 23, 2026
A retrospective study by researchers in Turkey looked at a simple index based on three routine blood measurements: platelets, albumin and bilirubin. The “PALBI” index reflects how pulmonary hypertension affects both the heart and the liver. Researchers applied it to 3,432 people, including 1,520 patients with pulmonary hypertension identified by…
Read More
United Therapeutics (UTHR) Opens Xeno Organ Production Sites In Houston And Stewartville, Simply Wall Street, October 24, 2026
With its new facilities in Houston and Stewartville, United Therapeutics is turning its organ programme from an idea into a concrete part of the business. Rather than relying only on its lung medicines to grow, the company is now investing in physical sites to build a second line of business:…
Read More
Impaired BMPR2 signalling across pulmonary hypertension subgroups: a multicentre study, European Respiratory Journal Open Research, September 28, 2026
A multicentre German study, run at specialist centres in Heidelberg, Hannover and Giessen/Marburg, looked at the key gene in pulmonary hypertension, BMPR2. Changes in this gene cause most inherited cases of pulmonary arterial hypertension, and the biological pathway it controls is also the target of sotatercept. The researchers took blood…
Read More
Researchers at Brown University, USA, find that molecular profiles may help create more effective individualized treatment for pulmonary arterial hypertension, The Brown Daily Herald, October 15, 2026
In a retrospective study, researchers at Brown University looked back at data from patients with pulmonary arterial hypertension. Their cells had been collected from the lung blood vessels during routine catheter procedures. After they collected the cells, the researchers sequenced the cells’ RNA content. Next, they used a bioinformatics pipeline…
Read More
Sotatercept in Paediatric Pulmonary Hypertension: Experience from the Pediatric Pulmonary Hypertension Network, CHEST Journal, October 5, 2026
Despite robust evidence in adult patients, up to now there was limited data on the use of sotatercept in pediatric pulmonary hypertension patients. The findings of a multi-center, retrospective study of children and young adults ≤ 21 years of age with paediatric pulmonary hypertension, treated by programs in the Pediatric…
Read More
Contemporary Economic, Hospitalization, and Mortality Burden Among Pulmonary Arterial Hypertension Patients: A Real-World US Claims Data Analysis, Pulmonary Circulation, October 6, 2026
A study using United States insurance claims data looked at the real-world burden of pulmonary arterial hypertension in 2,712 treated adults between 2017 and 2024 (average age 62, 69% women). Over an average follow-up of just over two years: The authors conclude that, despite recent advances in treatment, the disease…
Read MoreGossamer submits New Drug Application to the US Food and Drug Administration (FDA) for seralutinib in pulmonary arterial hypertension (PAH)
Gossamer Bio has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for seralutinib in pulmonary arterial hypertension (PAH). A New Drug Application is the formal application requesting that the Food and Drug Administration review a medicine to determine whether it may be approved for…
Read MoreEvery Breath Counts: The Evolving Role of Inhaled Therapies in pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD), European Medical Journal, October 20, 2026
This article contains an abstract and full transcript of a symposium which took place on 6th September 2026, as part of the European Respiratory Society (ERS) Congress held in Barcelona, Spain, sponsored by INSMED. The Chairperson was Professor Jean-Luc Vachiery and the speakers were Professors Irene Lang (Medical University, Vienna,…
Read More
Estimating mean pulmonary arterial pressure (mPAP) in the machine learning era, European Respiratory Journal, October 9, 2026
Accurate assessment of mean pulmonary arterial pressure (mPAP) is key to the diagnosis, haemodynamic classification and follow-up of pulmonary hypertension. The article, authored by French researcher at Le Kremlin-Bicêtre, France, requires permissions in order to access the full text, so we are only able to use the shareable abstract which…
Read More
Global data on pulmonary arterial hypertension in people aged 60 and over reveals diverging trajectories in rich and poor nations, Pulmonary Hypertension News, October 12, 2026
On October 12, 2026, Pulmonary Hypertension News published an article by Marisa Horak MS summarising the findings of a study by researchers at Ningxia Medical University in China, published in Pulmonary Circulation. The study looked at global data on pulmonary arterial hypertension in people aged 60 and over between 1990…
Read More
Treatment Strategies for Achieving and Maintaining Low-Risk Status in Pulmonary Arterial Hypertension: A Systematic Review, Cureus, October 18, 2026
Reaching and keeping low-risk status is now the main treatment goal in pulmonary arterial hypertension, but the evidence on which treatments help patients get there is spread across many studies using different risk tools. A systematic review was conducted by researchers in the UK following the Preferred Reporting Items for…
Read More
Alaunos Therapeutics has bought Velaris Therapeutics, which is developing four biological drugs for pulmonary arterial hypertension (PAH) and related heart and lung diseases, October 13, 2026
The pipeline VLR199 (the lead candidate): works in the same way as sotatercept (Winrevair), by trapping proteins of the activin family that drive the abnormal growth of cells in the lung vessels. The aim is to improve on aspects of sotatercept that may not be “fully optimised”. First clinical results…
Read MoreSomething went wrong. Please refresh the page and/or try again.
Archive (1165) News (873) Save the date (4)
AI (3) America (17) Asia (13) biomarkers (3) BMPR2 (3) clinical trials (3) Colombia (3) CTEPH (7) Deutsch (3) diagnosis (9) diagnostics (3) Digital health (3) ELF (3) EMA (3) English (4) ERS (3) ESOT (4) Europe (34) Francais (9) genetics (4) German (4) Germany (3) health technology assessment (3) Hipertensión Pulmonar (2) HTA (3) HTAP (5) Italiano (6) Latinamerica (14) Lungenhochdruck (3) PAH (9) PAHSSc (6) PH (3) PHA (11) PHA UK (8) pulmonary artery denervation (3) QOL (3) quality of life (3) remote monitoring (4) RHC (4) right heart catheterisation (3) scleroderma (3) sotatercept (5) Spain (3) Telemedicine (3) Turkish (7)